Advertisement

Der Urologe

, Volume 51, Issue 9, pp 1240–1245 | Cite as

Intermittierende Hormontherapie beim androgensensiblen Prostatakarzinom

Sinn oder Unsinn?
  • P. Thelen
  • R.-H. Ringert
  • H. LoertzerEmail author
  • A. Strauß
Übersichten
  • 166 Downloads

Zusammenfassung

Die Androgendeprivation ist die wesentliche Therapie des fortgeschrittenen Prostatakarzinoms. Obwohl sich die Hinweise mehren, dass eine phasenweise Unterbrechung des Hormonentzugs die damit verbundenen Nebenwirkungen vermindern kann, besteht bis heute keine generelle Empfehlung für die intermittierende Hormondeprivation. Vorliegende Metaanalysen von klinischen Studien legen aber den Schluss nahe, dass die Variante der Androgendeprivation einen Gewinn an Lebensqualität bei unvermindertem Therapieerfolg gewähren kann. Zudem zeigen aktuelle präklinische Studien zusätzliches Potenzial einer intermittierenden Androgendeprivation auf. Zukünftige Studien müssen es jedoch noch bestätigen, dass sich diese Therapievarianten am Prostatakarzinompatienten umsetzen lassen.

Schlüsselwörter

Prostatakarzinom, kastrationsresistentes Androgenentzug Androgendeprivation, intermittierende Lebensqualität Testosteronsubstitution 

Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer

Sense or nonsense?

Abstract

Androgen deprivation is the predominant therapy for advanced prostate cancer. There is accumulating evidence that phases of intermission in androgen deprivation may have benefits regarding side effects, albeit there is as yet no general recommendation for intermittent androgen deprivation therapy. Recent systematic reviews at least substantiate a benefit from such regimens for general quality of life without therapy compromisation. In addition, preclinical data revealed further potential strategies for intermittent androgen deprivation therapy. Future studies must prove, however, that such approaches can be implemented in the clinical situation.

Keywords

Prostate cancer, castration-resistant Androgen withdrawal Androgen deprivation, intermittent Quality of life Testosterone replacement 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Buchan NC, Goldenberg SL (2010) Intermittent versus continuous androgen suppression therapy: do we have consensus yet? Curr Oncol 17(Suppl 2):45–48CrossRefGoogle Scholar
  2. 2.
    Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583PubMedCrossRefGoogle Scholar
  3. 3.
    Schally AV, Kastin AJ, Arimura A (1971) Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 22(11):703–721PubMedGoogle Scholar
  4. 4.
    Börgermann C, Loertzer H, Hammerer P et al (2010) Probleme, Zielsetzung und Inhalt der Früherkennung beim Prostatakarzinom Urologe A 49(2):181–189Google Scholar
  5. 5.
    Klotz LH, Herr HW, Morse MJ et al (1986) Intermittent endocrine therapy for advanced prostate cancer. Cancer 58(11):2546–2550PubMedCrossRefGoogle Scholar
  6. 6.
    Garnick MB (1999) Hormonal therapy in the management of prostate cancer: an historical overview. Mol Urol 3(3):175–182PubMedGoogle Scholar
  7. 7.
    Akakura K, Bruchovsky N, Goldenberg SL et al (1993) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71(9):2782–2790PubMedCrossRefGoogle Scholar
  8. 8.
    Young CY, Montgomery BT, Andrews PE et al (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51(14):3748–3752PubMedGoogle Scholar
  9. 9.
    Cattabiani C, Basaria S, Ceda GP et al (2011) Relationship between Testosterone deficiency and Cardiovascular risk and Mortality in Adult Men. J Endocrinol Invest 35(1):104–120PubMedGoogle Scholar
  10. 10.
    Azoulay L, Yin H, Benayoun S, Renoux C et al (2011) Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60(6):1244–1250PubMedCrossRefGoogle Scholar
  11. 11.
    Tunn U (2007) The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99(Suppl 1):19–22PubMedCrossRefGoogle Scholar
  12. 12.
    Conti PD, Atallah AN, Arruda H et al (2007) Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 17(4):CD005009Google Scholar
  13. 13.
    Abrahamsson PA (2010) Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 57(1):49–59PubMedCrossRefGoogle Scholar
  14. 14.
    Calais de Silva FEC, Bono AV, Whelan P et al (2007) Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Urooncological Group. Eur Urol 55(6):1269–1277CrossRefGoogle Scholar
  15. 15.
    Miller K, Steiner U, Lingnau A et al (2007) Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 25:238Google Scholar
  16. 16.
    Verhagen PCMS, Wissenburg LD, Wildhagen MF et al (2008) Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. Eur Urol 7(Suppl 3):206Google Scholar
  17. 17.
    Klotz L, O’Callaghan CJ, Ding K et al (2011) A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 29(Suppl 7)Google Scholar
  18. 18.
    Buchan NC, Goldenberg SL (2010) Intermittent androgen suppression for prostate cancer. Nat Rev Urol 7(10):552–560PubMedCrossRefGoogle Scholar
  19. 19.
    Scholz MC, Jennrich RI, Strum SB et al (2006) Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. J Urol 175(5):1673–1678PubMedCrossRefGoogle Scholar
  20. 20.
    Klotz L, Goldenberg SL (2010) Multicenter doubleblind study comparing 0.5 mg dutasteride versus placebo daily in men receiving intermittent androgen ablation therapy for prostate cancer („AVIAS“). http://clinicaltrials.gov/ct2/show/NCT00553878Google Scholar
  21. 21.
    Bruchovsky N, Klotz L, Crook J et al (2007) Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109(5):858–867PubMedCrossRefGoogle Scholar
  22. 22.
    Harman SM, Metter EJ, Tobin JD et al (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86(2):724–731PubMedCrossRefGoogle Scholar
  23. 23.
    Kaminsky A, Sperling H (2010) Testosteronsubstitutionstherapie beim Prostatakarzinom. Urologe A 49(1):20–25PubMedCrossRefGoogle Scholar
  24. 24.
    Chuu CP, Kokontis JM, Hiipakka RA et al (2011) Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 18:63PubMedCrossRefGoogle Scholar
  25. 25.
    Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen dependent growth. Eur Urol 55:310–320PubMedCrossRefGoogle Scholar
  26. 26.
    Mathew P (2008) Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial. Ann Oncol 19:395–396PubMedCrossRefGoogle Scholar
  27. 27.
    Pfitzenmaier J, Altwein JE (2009) Hormonal therapy in the elderly prostate cancer patient. Dtsch Ärztebl Int 106(14):242–247PubMedGoogle Scholar
  28. 28.
    Knudsen KE, Penning TM (2010) Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 21(5):315–324Google Scholar
  29. 29.
    Tsihlias J, Zhang W, Bhattacharya N et al (2000) Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene. 3;19(5):670–679Google Scholar
  30. 30.
    Watson PA, Chen YF, Balbas MD et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107(39):16759–16765PubMedCrossRefGoogle Scholar
  31. 31.
    Chang KH, Li R, Papari-Zareei M, Watumull L et al (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108(33):13728–13733PubMedCrossRefGoogle Scholar
  32. 32.
    Ohlmann CH, Kamradt J, Stöckle M (2011) Antihormonelle Therapie des Prostatakarzinoms der 3. Generation. Urologe A (Epub ahead of print) Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • P. Thelen
    • 1
  • R.-H. Ringert
    • 1
  • H. Loertzer
    • 1
    Email author
  • A. Strauß
    • 1
  1. 1.Urologische Klinik und PoliklinikGeorg-August-Universität GöttingenGöttingenDeutschland

Personalised recommendations